Literature DB >> 33773119

REPLACE and the role of riociguat in pulmonary arterial hypertension therapy.

Robert P Frantz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33773119     DOI： 10.1016/S2213-2600(20)30567-1

Source DB:  PubMed          Journal:  Lancet Respir Med        ISSN： 2213-2600            Impact factor:   30.700


× No keyword cloud information.
  3 in total

Review 1.  Therapeutic augmentation of NO-sGC-cGMP signalling: lessons learned from pulmonary arterial hypertension and heart failure.

Authors:  Filippos Triposkiadis; Andrew Xanthopoulos; John Skoularigis; Randall C Starling
Journal:  Heart Fail Rev       Date:  2022-04-18       Impact factor: 4.654

2.  Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat.

Authors:  Franck F Rahaghi; Vijay P Balasubramanian; Robert C Bourge; Charles D Burger; Murali M Chakinala; Michael S Eggert; Jean M Elwing; Jeremy Feldman; Christopher King; James R Klinger; Stephen C Mathai; John Wesley McConnell; Harold I Palevsky; Ricardo Restrepo-Jaramillo; Zeenat Safdar; Jeffrey S Sager; Namita Sood; Roxana Sulica; R James White; Nicholas S Hill
Journal:  Pulm Circ       Date:  2022-04-07       Impact factor: 2.886

3.  Soluble Guanylate Cyclase Stimulators (Riociguat) in Pulmonary Hypertension: Data from Real-Life Clinical Practice in a 3-Year Follow-Up.

Authors:  Fernanda Brum Spilimbergo; Taís Silveira Assmann; Marcelo Bellon; Laís Machado Hoscheidt; Cássia Ferreira Braz Caurio; Márcia Puchalski; Bruno Hochhegger; Gabriela Roncato; Gisela Martina Bohns Meyer
Journal:  Arq Bras Cardiol       Date:  2022-05-09       Impact factor: 2.667
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.